Trials / Conditions / Refractory Cytopenia With Multilineage Dysplasia

Refractory Cytopenia With Multilineage Dysplasia

13 registered clinical trials studyying Refractory Cytopenia With Multilineage Dysplasia.

Status	Trial	Sponsor	Phase
Completed	Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Completed	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255	National Cancer Institute (NCI)	Phase 2
Completed	Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome NCT01165996	Case Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High- NCT00988715	Fred Hutchinson Cancer Center	Phase 1
Completed	Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT NCT01012492	Boston Children's Hospital	Phase 2
Terminated	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Dono NCT00589316	Fred Hutchinson Cancer Center	Phase 1
Completed	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myelo NCT00462605	National Cancer Institute (NCI)	Phase 2
Completed	Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813	Fred Hutchinson Cancer Center	Phase 2
Completed	Vorinostat in Treating Patients With Acute Myeloid Leukemia NCT00305773	National Cancer Institute (NCI)	Phase 2
Completed	Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes NCT00104962	National Cancer Institute (NCI)	Phase 1
Terminated	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Trans NCT00119366	Fred Hutchinson Cancer Center	Phase 2
Completed	Tipifarnib in Treating Patients With Myelodysplastic Syndromes NCT00005845	National Cancer Institute (NCI)	Phase 1
Completed	Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177	Fred Hutchinson Cancer Center	Phase 1